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Abstract 
Background 
Men considering the prostate specific antigen (PSA) test for prostate cancer, an increasingly common male cancer, are encouraged to 
make informed decisions, as the test is limited in its accuracy and the natural history of the condition is poorly understood. The Web-
based PSA decision aid, Prosdex, was developed as part of the UK Prostate Cancer Risk Management Programme in order to help men 
make such informed decisions. 
Objectives 
The aim of this study was to evaluate the effect of the Web-based PSA decision aid, Prosdex, on informed decision making. 
Methods 
A Web-based randomized controlled trial was conducted in South Wales, United Kingdom. Men aged 50 to 75 who had not previously 
had a PSA test were randomly allocated to two intervention and two control groups. Participants in the intervention groups either viewed 
Prosdex or were given a paper version of the text. The main outcome measures were the three components of informed decision 
making: (1) knowledge of prostate cancer and PSA, (2) attitude toward PSA testing, (3) behavior using a proxy measure, intention to 
undergo PSA testing. Decisional conflict and anxiety were also measured as was uptake of the PSA test. Outcomes were measured by 
means of an online questionnaire for the Prosdex group, the paper version group, and one of two control groups. Six months later, PSA 
test uptake was ascertained from general practitioners’ records, and the online questionnaire was repeated. Results are reported in 
terms of the Mann-Whitney U-statistic divided by the product of the two sample sizes (U/mm), line of no effect 0.50. 
Results 
Participants were 514 men. Compared with the control group that completed the initial online questionnaire, men in the Prosdex group 
had increased knowledge about the PSA test and prostate cancer (U/mn 0.70; 95% CI 0.62 - 0.76); less favourable attitudes to PSA 
testing (U/mn 0.39, 95% CI 0.31 - 0.47); were less likely to undergo PSA testing (U/mn 0.40, 95% CI 0.32 - 0.48); and had less 
decisional conflict (U/mn 0.32, 95% CI 0.25 - 0.40); while anxiety level did not differ (U/mn 0.50, 95% CI 0.42 - 0.58). For these 
outcomes there were no significant differences between men in the Prosdex group and the paper version group. However, in the 
Prosdex group, increased knowledge was associated with a less favourable attitude toward testing (Spearman rank correlation [ρ] = -
0.49, P < .001) and lower intention to undergo testing (ρ = -0.27, P = .02). After six months, PSA test uptake was lower in the Prosdex 
group than in the paper version and the questionnaire control group (P = .014). Test uptake was also lower in the control group that did 
not complete a questionnaire than in the control group that did, suggesting a possible Hawthorne effect of the questionnaire in favour of 
PSA testing. 
Conclusions 
Exposure to Prosdex was associated with improved knowledge about the PSA test and prostate cancer. Men who had a high level of 
knowledge had a less favourable attitude toward and were less likely to undergo PSA testing. Prosdex appears to promote informed 
decision making regarding the PSA test. 
Trial Registration 
ISRCTN48473735; http://www.controlled-trials.com/ISRCTN48473735 (Archived by WebCite at http://www.webcitation.org/5r1TLQ5nK) 
Keywords: Decision aid, Informed decision making, Internet, Prostate cancer, Prostate Specific Antigen (PSA) test 
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Introduction 
Informed decision making is difficult to deliver for men who are considering the prostate specific antigen (PSA) test. Web-based PSA 
decision aids potentially provide a solution. 
The decision to undergo PSA testing for prostate cancer is a very difficult one for men. On the one hand, the disease is gaining 
prominence, largely due to an aging population and increased detection. On the other hand, the usefulness of the only widely available 
test for prostate cancer, PSA, is limited not only by its poor sensitivity and specificity but also by the uncertainty relating to the natural 
history and the management of the disease [1,2]. It is for this reason that the UK National Cancer Screening Programme in 2001 
established the Prostate Cancer Risk Management Programme (PCRMP), a strategy that had, as one of its key goals, the promotion of 
informed decision making about PSA testing [2]. An informed decision, as outlined in the measure of informed decision making 
developed by Marteau et al for prenatal Down’s syndrome testing [3,4], could be characterized by relevant knowledge of the subject as 
well as by attitudes congruent with subsequent behavior. In the case of PSA testing, therefore, what was important was not the actual 
decision made vis-à-vis the test. Instead, the aim of the PCRMP was for men to both acquire knowledge about PSA and prostate cancer 
and make decisions about the test that reflected their attitudes toward it. 
In order to facilitate informed decision making, all general practitioners (GPs) in the United Kingdom were provided with information 
leaflets about PSA testing to be provided to patients on request. Nonetheless, it was accepted by policymakers that a more publicly 
engaging source of information was required. Consequently, attention turned to decision aids, which already had a strong record in 
facilitating difficult decisions across a range of conditions including prostate cancer [5]. In addition, the Web was identified as a suitable 
medium for delivering these decision aids to UK men. Therefore, the Web-based PSA decision aid, Prosdex [6], was commissioned by 
Cancer Research UK and launched in 2004. It was, and remains, an innovative intervention in eHealth, combining text and multimedia 
features with deliberation tools designed to directly promote informed decision making, reflecting the standards set by the International 
Patient Decision Aid Collaboration [7]. 
It is not known whether PSA decision aids have an effect on informed decision making. Systematic reviews have consistently shown 
these aids improve knowledge about PSA and prostate cancer, which is the initial, essential component of informed decision making 
[5,8-10]. In addition, PSA decision aids have been shown to affect behavior, that is, use of these aids typically results in a reduced 
likelihood of PSA testing [8,9]. However, to date there is no evidence that such conservative behavior is associated with greater 
knowledge of prostate cancer and PSA testing and with negative attitudes toward the test, as would be expected with informed decision 
making.  
There is no specific measure of informed decision making in PSA testing, and therefore, for this study, a composite evaluation was used 
based on three key components: knowledge, attitude, and behavior. Knowledge about PSA and prostate cancer was taken as the 
principal outcome for the study due to its key role in informed decision making: without knowledge, informed decision making cannot 
take place. The behavior component assessed was intention to undertake PSA testing, and this was measured at the same time as the 
attitude toward the PSA test. Crucially, to determine an effect on informed decision making, correlations between the knowledge, 
attitude, and behavior outcomes were examined. Our hypothesis was that, at group level, men using the Prosdex Web-based PSA 
decision aid would improve their knowledge and thereby develop both a less favorable attitude toward the test and a reduced intention to 
undergo testing, principally because increased knowledge would lead to an understanding of the uncertain benefits of the PSA test. 
Finally, six months later, we evaluated a second behavioral outcome, PSA test uptake. The hypothesis here, for the same reasons, was 
that PSA test uptake would be reduced in those men who had demonstrated informed decision making. 
The potential of the Web was exploited in two ways in this study. First, as described, the decision aid was hosted on the Web. Second, 
an online research methodology was employed, namely, a four-armed randomized controlled trial with two intervention and two control 
groups, which allowed a comparison between Prosdex and a control group, between Web-based Prosdex and a paper version of the 
same information, and, between the two control groups in order to consider the Hawthorne effect of an outcome questionnaire. Our 
expectation was that participants presented with the questionnaire would be more likely to undertake PSA testing due to an increased 
awareness of the subject and exposure to popular opinions and media coverage, which tend to be uncritically positive about the benefits 
of PSA testing. The aim of this study, therefore, was to evaluate the effect of a Web-based PSA decision aid, Prosdex, on knowledge, 
attitudes and behavior—the components of informed decision making—using a Web-based questionnaire. 
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Methods 
Study Design 
A Web-based randomized controlled trial (RCT) was designed, composed of four groups: two intervention groups and two control 
groups. 
Setting 
Men were invited to participate by their general practitioners (GPs) in South Wales, United Kingdom. 
Participants 
Inclusion Criteria  
Men aged 50 to 75 were invited to participate. This is the age range in which men typically request or are offered the PSA test. The 
participants accessed the study via the Internet and had to be able to use a computer, and they were asked to indicate this on the 
consent form. Those unable to participate due to inability to use a computer and those who did not respond to the invitation were 
counted separately, in line with CONSORT guidelines [11]. 
Exclusion Criteria  
Participants who could not read English were excluded, as were those whose general practice records indicated that they had previously 
had prostate cancer or a PSA test. 
Recruitment Process  
Potential participants were identified from electronic patient registers. A staff member from each practice generated a list of potential 
participants aged 50 to 75 who had not had a PSA test or prostate cancer. A random sample of 100 men was selected from the list. A 
staff member with knowledge of the patients—usually a GP—was asked to screen out men who were unsuitable for the trial due to 
serious ill-health, specifically a terminal illness, dementia, or severe mental illness. Finally, invitation letters signed by the GP, participant 
information sheets, and consent forms were sent by mail to eligible potential participants. 
Affirmative consent forms from each practice were transferred to the research officer (author NJ-W) who allocated each participant with a 
number provided remotely by the trial statistician (author RN) to ensure concealment. The process ensured individual level 
randomization to one of two intervention groups or to one of two control groups, as we were interested in individual decision making after 
an intervention used independently by each participant. There was unlikely to be an intracluster correlation for these outcomes, because 
men would view the Web at home [12]. 
Sample Size  
The sample size aimed for was 600 participants: 150 in each of the four groups. This figure was derived from our systematic review of 
PSA decision aids in which these interventions were found to have resulted in knowledge that had improved by 19.5% (SD 45.1) [9]. 
Thus, 150 men per group would allow the detection of a 20% absolute difference in knowledge with power greater than 90%. Assuming 
a recruitment rate of 30%, we aimed to invite 2000 potential participants from 20 GP practices, 100 men from each practice [13]. 
Intervention and Controls 
The intervention used in this study, the Web-based PSA decision aid Prosdex [6], presents evidence-based information about prostate 
cancer and PSA testing, encouraging users to weigh the pros and cons of testing [14]. In addition, Prosdex includes video clips of 
enacted patient experiences about the PSA test and subsequent investigations and treatments. There is also information about shared 
decision making and a deliberation tool named a “decision stacker,” which visualizes attitudes toward the PSA test. Prosdex aims to 
actively encourage informed decision making. A specific version of the Prosdex website was developed for the study. Participants in the 
Prosdex intervention group were able to view the intervention in their own homes or in other settings. Participants in the second 
intervention, the paper version group, received a paper document, comprising the text of the website but not the name, to reduce the risk 
of participants in this group discovering Prosdex on the Web. Participants in the control groups received neither the Prosdex URL nor the 
paper version of the website (Figure 1). 
Outcomes 
Components of informed decision making were evaluated. Components were: (1) knowledge of prostate cancer and PSA, the primary 
outcome of the study; (2) attitude toward PSA testing; and (3) behavior, using the proxy measure of intention to undergo PSA testing. 
Knowledge, attitude, and intention were assessed by a set of questions previously used in an evaluation of a brief paper-based PSA 
decision aid [15]. Twelve true or false questions were posed, and participants received a score of 1 for a correct answer, -1 for an 
incorrect answer, and 0 for unanswered items. In the attitude section, twelve statements, six favorable and six unfavorable to PSA 
testing, were presented. For the intention outcome, a single item question with a five-point Likert-like response scale, “How likely are you 
to have the PSA test?” was used, and a mean rank score was then calculated for each group. 
Two other outcomes, anxiety and decisional conflict, were measured by the questionnaire as these are outcomes that are commonly 
used in evaluations of decision aids [9]. Anxiety was assessed using the six-item short form of the Spielberger State Anxiety Inventory 
[16,17], and decisional conflict was measured by the Decisional Conflict Scale (DCS) [18,19]. Finally, at 6-months post intervention, 
actual uptake of the PSA test was measured. 
Measurement of Outcomes 
Baseline Outcomes Immediately Following the Intervention  
Data for all outcomes, apart from test uptake, were gathered from responses to an online questionnaire. Participants allocated to the two 
intervention groups (the Prosdex group and the paper version group) and the first control group (named the “questionnaire control 
group”) were asked to complete a questionnaire. These 3 groups were asked to access the study website using a unique password that 
was provided them. Participants’ exposure to interventions and the questionnaire is shown in Figure 1, as is the pathway for participants 
in the second control group. The second control group, which was not asked to complete a questionnaire, was named the “no 
questionnaire control group.” The data were collected in an SQL-server database, transferred to Excel spreadsheets, and analyzed 
using SPSS, version 12 (SPSS Inc, Chicago, IL, USA). 
Outcomes at Six Months  
At 6 months after the participants were allocated to the four groups, GPs were asked to review participants’ medical records to ascertain 
whether participants had had a PSA test in the 6-month interval. All participants, including those in the no questionnaire control group, 
were also asked to repeat the online questionnaire in order to evaluate any changes to the baseline outcomes, such as knowledge, over 
a 6-month period. 
Comparisons and Statistical Analysis 
To determine the effect on informed decision making, the main comparison was Prosdex group versus questionnaire control group. 
There were also two other comparisons. The first was the Prosdex group versus the paper version group to compare the effect of format 
and media. Also compared were the questionnaire control group versus the no questionnaire control group to assess the Hawthorne 
effect of the questionnaire on PSA testing as our expectation was that answering the questionnaire itself would encourage PSA testing. 
Also, in order to further assess the effect on informed decision making, correlations between knowledge, attitudes, and behavior 
outcomes were examined. 
Most of the analyses in this study were undertaken on a group basis. However, according to the model of informed decision making, we 
should be able to demonstrate high knowledge, negative attitude/intention, and reduced uptake of PSA testing at the level of an 
individual participant as evidence of informed decision making by the individual. The data were therefore analyzed accordingly, and 
participants whose knowledge scores were above the median were defined as “high knowledge.” The attitude and intention outcomes 
were then also dichotomized on the basis of the median scores to “high” and “low.” Finally, the PSA test uptake data for individuals were 
analyzed in relation to the dichotomized outcomes, and the odds ratios for test uptake were calculated. 
Comparability of the four groups for characteristics of age, ethnicity, marital status, and education was assessed. Demographic data for 
the two intervention groups and the questionnaire control group were obtained from the baseline questionnaire, and demographic data 
for the no questionnaire control group was obtained from the 6-month follow-up questionnaire. Outcomes were compared between 
groups on an ”intention to treat” basis. Results were reported in terms of an effect size derived from the Mann-Whitney U-statistic divided 
by the product of the two samples sizes (U/mn) [20]. The statistic U/mn is applicable to continuous and ordinal outcomes alike. The 
expected value under the null hypothesis is 0.5, and the measure takes the value 0 or 1 in extreme cases in which there is no overlap 
between the two samples. Therefore, for comparisons, U/mn is greater than 0.5 when the first group scores higher than the first; also, for 
confidence intervals, the line of no effect is set at 0.5 [20]. 
The study received ethical approval from South East Wales Research Ethics Committee (REC reference number 06/WSE04/13). All 
participants gave informed consent before taking part in the trial. 
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Results 
Recruitment of General Practices 
We invited 60 general practices from 9 Local Health Board (primary care organization) areas in South Wales. Of these, 27 practices 
agreed to participate, 33 declined, and 2 subsequently withdrew. 
Recruitment of Participants 
In 2008, 25 practices were sent 100 invitations each, and in response to lower than anticipated recruitment, 11 of these practices agreed 
to send an additional 100 invitations. A total of 3600 invitations were sent. Consent forms were returned from 646 potential participants 
(18%), of whom 565 (16%) agreed to participate. Excluded were 51 participants due to reported difficulties with Internet access and/or 
computer literacy, giving a final number of 514 participants (Figure 1). Of the 382 participants allocated to the Prosdex group, the paper 
version group, and the questionnaire control group, 278 (73%) completed the first online questionnaire in 2008. For the comparison of 
the Prosdex group versus the questionnaire control group, 89 versus 103 participants, a power of 87% was achieved to detect a 20% 
improvement in knowledge. For the Prosdex group versus the paper version group, 89 versus 86 participants, a power of 85% was 
achieved to detect a 20% improvement in knowledge. 
Characteristics of Participants 
Details of participant characteristics are given in Table 1. Of the participating men, 236 of 379 (62%), were between 50 and 59 years of 
age, 367 (97.4%) were white, 79 (88%) were married or cohabitating, and 334 (45%) had either a college or university degree, indicating 
volunteer bias towards those who are younger and those with higher educational attainments. There were no statistically significant 
differences between the groups. 
Comparisons and Correlations at Baseline 
The two sets of comparisons at baseline, the Prosdex group versus the questionnaire control group and the Prosdex group versus the 
paper version group, are demonstrated in Table 2 with U/mn values. Results shown in Table 2 are based on 278 to 283 participants for 
whom full data were available. For the main comparison, the Prosdex group versus the questionnaire control group, participants in the 
Prosdex group were found to have significantly higher knowledge scores than those in the questionnaire control group. Men in the 
Prosdex group also had less favorable attitudes to the PSA test than those in the questionnaire control group, and intention to undergo 
PSA testing was lower in the Prosdex group than in the questionnaire control group. The decisional conflict score was lower in the 
Prosdex group than in the questionnaire control group, and there was no statistical difference between the two groups in terms of their 
anxiety regarding the PSA test. 
Regarding the Prosdex group versus the paper version group, there was no significant difference in the knowledge scores of the 
participants. However, the mean knowledge score was slightly higher in the paper version group than in the Prosdex group (5.4 out of 12 
vs 4.9 out of 12). Also, no significant differences were found between the Prosdex and the paper version groups in attitude toward PSA 
testing, intention to undergo PSA testing, decisional conflict score, and anxiety outcomes. 
The correlations between outcomes are shown in Table 3. There was a substantial inverse correlation between overall knowledge and 
attitude scores in the two intervention groups but not in the questionnaire control group. That is, greater knowledge was associated with 
a less favorable attitude toward the test in the two intervention groups. There was also a negative correlation between knowledge and 
intention to undergo PSA testing in the Prosdex group but not in the other two groups. In other words, for participants in the Prosdex 
group alone, greater knowledge was associated with reduced intention to take the PSA test. For all three groups, attitude and intention 
outcomes were strongly correlated. Therefore, as hypothesized at the outset of the study, participants in the Prosdex group 
demonstrated greater knowledge and had negative but congruent attitudes and behavior. 
Comparisons at 6-month Follow-up  
Although the trial design was not powered to demonstrate a difference at the level of PSA test uptake, there was a difference between 
the groups which achieved statistical significance. As shown in Table 4, PSA uptake by men in the Prosdex group was 3% (4/127) and in 
the questionnaire control group was 9% (11/123), P = .014. The Hawthorne effect of the questionnaire was also demonstrated, as the 
PSA test uptake in the no questionnaire control group was 2% (2/126), that is, less than that in the questionnaire control group. 
In Table 5 we demonstrate the odds ratio of PSA testing, for individual participants, with respect to dichotomized 
knowledge/attitude/intention. PSA testing was found to be increased twofold for individuals with high attitude and high intention in the 
presence of high knowledge, although the confidence intervals were very wide. Finally, at six months, as shown in Table 6, knowledge 
was found to be significantly lower in both intervention groups but particularly so in the paper version group. 
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Discussion 
Summary of Main Findings 
The Web-based decision aid was found to promote informed decision making about the PSA test. It increased knowledge about the PSA 
test and prostate cancer, generated less favorable attitudes to PSA testing, and lessened the intention to undergo testing. Participants 
who used Prosdex and who demonstrated a high level of knowledge had less favorable attitudes and lower intentions to undergo PSA 
testing. This congruence between attitude and intention in the context of higher knowledge accords with our definition of informed 
decision making in PSA testing. 
PSA test uptake was less in the no questionnaire control group than in the questionnaire control group, confirming the Hawthorne effect 
of increased testing in participants presented with the questionnaire. PSA test uptake was found to be lower in the Prosdex group than in 
the paper version group and the questionnaire control group, suggesting that, in effect, exposure to Prosdex counters the Hawthorne 
effect of participation, so that PSA uptake is more likely to return to background levels. Finally, the data suggested that individual 
participants with high knowledge but negative attitudes and intentions were less likely to undertake PSA testing. 
Strengths and Limitations of the Study 
This is the first Web-based four-arm randomized controlled trial of informed decision making in PSA testing that has evaluated a Web-
based PSA decision aid. The intervention has been shown to be associated with informed decision making and reduced PSA test 
uptake. The employment of an online questionnaire linked to a Web-based decision aid represents a departure from the traditional 
methods of evaluating decision aids where, normally, the participant would use the decision aid in a clinic setting, sometimes after 
seeing a clinician, and then be given a written questionnaire. A researcher would usually facilitate the whole process [10,21,22]. In 
contrast, participants in this trial used the decision aid and completed the online questionnaire in a setting of their choice, usually their 
own homes, with no training, thereby reducing researcher bias. In total, 514 participants were recruited for this study. This was less than 
the original recruitment target of 600 but sufficient to attain a power of 85% for the primary outcome, knowledge. Those men who did 
participate were mostly well educated and in the youngest of the three age groups, which limits the generalizability of the results. There 
was a significant loss to follow-up: 27% were lost between allocation and the first questionnaire despite use of a reminder questionnaire 
for those who initially failed to participate. 
The intervention used in the study, Prosdex, had previously been the subject of a rigorous development process, which included field-
testing [14,15], and the outcome measurements used in the questionnaire had previously been validated in other studies. The paper 
version of Prosdex contained the same textual information as the Web-based decision aid. However, participants in the paper version 
group retained their intervention while completing the questionnaire, unlike those in the Prosdex group who were led automatically from 
Prosdex to the online questionnaire and had no means of reviewing it while answering the questions. We have no means of ascertaining 
the impact of this potential contamination. Finally, the construction of the research website resulted in the baseline questionnaire being 
completed after viewing Prosdex, and it is possible that this may have had an effect on the impact of the intervention 
Comparison with Existing Literature 
This trial builds on earlier studies that have considered the effect of PSA decision aids on the constituent components of informed 
decision making: knowledge, attitude, and behavior. Knowledge, as previously noted, has consistently been shown to improve with PSA 
decision aids [8], and recent studies have shown this to be the case with Web-based PSA decision aids [10,23]. With respect to attitude, 
Watson et al, in their trial of a paper-based PSA decision aid, found that their decision aid led to a less favorable attitude to PSA testing. 
Finally, in terms of behavior, we previously found in a systematic review of PSA decision aids that PSA testing decreased by 3.5% after 
using this aid [9]. This finding was reinforced in a more recent review by Volk and colleagues who found that men given a decision aid 
were less likely to take the PSA test (odds ratio 0.88) [8]. None of these studies, however, considered the three components of informed 
decision together as in our trial. 
Implications for Research and Practice 
The controversy surrounding PSA testing has recently been reignited by two contrasting studies of prostate cancer screening, published 
simultaneously. First, a large European randomized study reported a 20% reduction in prostate cancer mortality. The authors estimated, 
however, that in order to prevent 1 death from prostate cancer, 1410 men would need to undergo PSA testing and 48 men would need 
to be treated for prostate cancer [24]. In the second study, another large randomized prostate cancer screening trial from the United 
States, no significant reduction in mortality was found after 7 to 10 years of follow-up [25]. Whatever the outcome of the screening 
debate, the fact remains that the PSA test has significant limitations and those men considering it will still require balanced information in 
order to make informed decisions. Moreover, the information will need to be easily and repeatedly accessible, as highlighted by the 
significant attrition in knowledge in this study after 6 months. The Web provides the ideal medium for this accessibility, and therefore, it is 
our opinion that it is not a question of whether Web-based PSA decision aids are required, but instead it is a question of how best to 
present the information to facilitate informed decision making. 
This study has demonstrated that the Web-based PSA decision aid Prosdex has a positive impact on informed decision making in 
accordance with the UK Prostate Cancer Risk Management Strategy [2]. However, to maximize its impact and benefit the greatest 
number of men, its use needs to be promoted among the public as well as among health professionals. Prosdex requires an 
implementation strategy. 
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Figures and Tables 
Figure 1 
 Prosdex 
RCT 
CONSORT 
participant 
flow chart 
Table 1 
Characterist
ics of trial 
participants 
Characteristic Prosdex Group  
n (%) 
Paper Version  
Group  
n (%) 
  
  
  
   
  
  
  
  
Age group 
 50-59 61 (68) 54 (63)       
Characteristic Prosdex Group  
n (%) 
Paper Version  
Group  
n (%) 
  
  
  
   
  
  
  
  
 60-69 22 (24) 27 (31)       
 70 or over 7 (8) 5 (6)       
Highest level of education 
 None 9 (10) 9 (11)       
 CSE or equivalent 7 (8) 3 (4)       
 O level or equivalent 10 (11) 16 (19)       
 A level or equivalent 9 (10) 8 (9)       
 Clerical or commercial 7 (8) 18 (21)       
 College or university degree 48 (53) 32 (37)       
Marital status 
 Married or cohabiting 79 (88) 76 (88)       
 Widowed 1 (1) 0 (0)       
 Never married 3 (3) 5 (6)       
Characteristic Prosdex Group  
n (%) 
Paper Version  
Group  
n (%) 
  
  
  
   
  
  
  
  
 Divorced or separated 7 (8) 5 (6)       
Ethnicity 
 White 89 (99) 83 (98)       
 Black African 0 (0) 0 (0)       
 Indian 0 (0) 0 (0)       
 Mixed race 1 (1) 2 (2)       
 Other 0 (0) 0 (0)       
Table 2 
Summary of outcome results 
Outcome Measure Prosdex Group vs Questionnaire Control Group       
Mean scores U/mn 95% CI          
Knowledge 4.90 vs 2.17 0.70 0.62 - 0.7           
Attitude 9.10 vs 11.90 0.39 0.31 - 0.4           
Intention to undergo PSA testinga 40% vs 58% 0.40 0.32 - 0.4           
Outcome Measure Prosdex Group vs Questionnaire Control Group       
Mean scores U/mn 95% CI          
DCS 40.37 vs 47.73 0.32 0.25 - 0.4           
Anxiety 4.98 vs 4.88 0.50 0.42 - 0.5           
a Figures reported for these cells are percentages of men who indicated they were very 
likely to or definitely would take the test. 
Table 3 
Correlation of knowledge, attitude, and intention outcomes for the Prosdex, paper 
version, and questionnaire control groups 
Outcome Intervention Group 
 Prosdex Group  
(n = 89) 
Pape     
(n = 8  
    
   
Knowledge-Attitude 
 Spearman rank correlation -0.49 -0.49  
 P valuea < .001 < .00   
Knowledge-Intention 
  
Spearman rank correlation 
 
-0.27 
 
-0.10 
 
 
 P valuea .01 .38  
Outcome Intervention Group 
 Prosdex Group  
(n = 89) 
Pape     
(n = 8  
    
   
Attitude-Intention 
 Spearman rank correlation 0.68 0.54  
 P valuea < .001 < .00    
a 2-tailed significance 
Table 4 
Percent PSA test uptake by group 
 Intervention and Control Groups (Percent Uptake) 
PSA Test Uptakea Prosdex  
Group 
Paper Version Group Question       
  
  
 
No PSA test 96.9 90.9 91.1   
PSA test 3.1 9.1 8.9   
a Pearson chi-square: P = .014 
Table 5 
Odds ratios showing the relationship of PSA test uptake to attitude and intention 
scores, dichotomized at their medians 
Dichotomized Outcome Odds Ratioa    
Dichotomized Outcome Odds Ratioa    
Attitude 1.80    
Intention 1.41    
a Based on 131 men with knowledge scores above the median on knowledge, and 
below the median on attitude and intention 
Table 6 
Mean knowledge scores at baseline and at 6 months by group 
 Intervention and Control Groupsa 
Timing of Questionnaire Prosdex Group  
(n = 47) 
Paper Version Group  
n = 57) 
   
   
   
  
    
Baseline 
 Mean knowledge scoreb 5.13 5.79   
6 months 
 Mean knowledge scoreb 3.70 3.96   
a Restricted to 273 men with full data available at both assessment points 
b Knowledge scale ranges from -12 to +12 
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